| Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 22719160 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Doxorubicin, an anthracycline antibiotic commonly used as a chemotherapeutic agent for breast cancer, is well known to cause cardiotoxicity. We report the case of an active, otherwise healthy 57-year-old breast cancer survivor who, 17 years after chemotherapy, presented with symptoms of overt heart failure. She had no cardiac risk factors, and neither laboratory nor imaging findings suggested myocarditis or dilated cardiomyopathy. Echocardiographic findings and differential diagnosis led us to attribute her condition to late doxorubicin-induced cardiomyopathy. By virtue of tapered medical therapy, her left ventricular ejection fraction improved from 0.20 to 0.55 in 8 months, and she was asymptomatic after 1 year. The reversibility of left ventricular dysfunction in our patient and the very late appearance of cardiotoxicity secondary to doxorubicin therapy raise questions about the pathogenesis and prevalence of late doxorubicin-induced cardiomyopathy and how to improve outcomes in patients who present with related symptoms of heart failure. |
| | |
Authors:
|
Simi Kumar; Ravi Marfatia; Susan Tannenbaum; Clifford Yang; Erick Avelar |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital Volume: 39 ISSN: 1526-6702 ISO Abbreviation: Tex Heart Inst J Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-06-21 Completed Date: 2012-10-29 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 8214622 Medline TA: Tex Heart Inst J Country: United States |
Other Details:
|
Languages: eng Pagination: 424-7 Citation Subset: IM |
Affiliation:
|
Departments of Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibiotics, Antineoplastic
/
adverse effects* Breast Neoplasms / drug therapy*, surgery Cardiomyopathies / chemically induced*, diagnosis, drug therapy, physiopathology Cardiovascular Agents / therapeutic use Chemotherapy, Adjuvant Doxorubicin / adverse effects* Electrocardiography Female Heart Failure / chemically induced, physiopathology Humans Magnetic Resonance Imaging Mastectomy, Segmental Middle Aged Recovery of Function Stroke Volume Time Factors Treatment Outcome Ventricular Dysfunction, Left / chemically induced, physiopathology Ventricular Function, Left |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Cardiovascular Agents; 23214-92-8/Doxorubicin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multiple instances of peripheral artery emboli from occult primary small cell lung cancer.
Next Document: The successful use of octreotide in the treatment of traumatic chylothorax.